MD3350223T2 - Anticorpi care se leagă specific la TL1A - Google Patents

Anticorpi care se leagă specific la TL1A

Info

Publication number
MD3350223T2
MD3350223T2 MDE20180714T MDE20180714T MD3350223T2 MD 3350223 T2 MD3350223 T2 MD 3350223T2 MD E20180714 T MDE20180714 T MD E20180714T MD E20180714 T MDE20180714 T MD E20180714T MD 3350223 T2 MD3350223 T2 MD 3350223T2
Authority
MD
Moldova
Prior art keywords
antibodies
tl1a
cystic fibrosis
disease
specifically bind
Prior art date
Application number
MDE20180714T
Other languages
English (en)
Inventor
Lynn Dorothy Poulton
Matthew Pollard
Anthony G Doyle
Bridget Ann Cooksey
Vanya Pande
Adam William Clarke
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MD3350223T2 publication Critical patent/MD3350223T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Sunt dezvăluiţi anticorpii variaţi exprimaţi recombinant care au afinitate crescută pentru TL1A şi potenţă crescută în comparaţie cu anticorpul mamă de la care au fost obţinuţi. Anticorpii inhibă interacţiunea dintre TL1A şi receptorul de deces 3 (DR3). Anticorpii sau compoziţia lor pot fi folosiţi pentru a trata unul sau mai multe dintre următoarele: astm, BPOC, fibroză pulmonară, fibroză chistică, boală inflamatorie a intestinului, boală gastrointestinală asociată cu fibroză chistică, boala Crohn, colită, colită ulceroasă, sindrom de colon iritabil. , esofagită eozinofilică, dermatită atopică, eczemă, sclerodermie, artrită sau artrită reumatoidă.
MDE20180714T 2015-09-18 2016-09-16 Anticorpi care se leagă specific la TL1A MD3350223T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220442P 2015-09-18 2015-09-18
PCT/US2016/052040 WO2017049024A1 (en) 2015-09-18 2016-09-16 Antibodies that specifically bind to tl1a

Publications (1)

Publication Number Publication Date
MD3350223T2 true MD3350223T2 (ro) 2020-09-30

Family

ID=57043002

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180714T MD3350223T2 (ro) 2015-09-18 2016-09-16 Anticorpi care se leagă specific la TL1A

Country Status (33)

Country Link
US (3) US10138296B2 (ro)
EP (2) EP3693393A1 (ro)
JP (2) JP7013366B2 (ro)
KR (1) KR101998535B1 (ro)
CN (1) CN108137693B (ro)
AR (1) AR106055A1 (ro)
AU (2) AU2016323460B2 (ro)
BR (2) BR122021002400A8 (ro)
CA (1) CA2997015A1 (ro)
CL (1) CL2018000711A1 (ro)
CO (1) CO2018003736A2 (ro)
CY (1) CY1123499T1 (ro)
DK (1) DK3350223T3 (ro)
EA (1) EA201890756A1 (ro)
ES (1) ES2810751T3 (ro)
HK (2) HK1251002A1 (ro)
HR (1) HRP20201323T1 (ro)
HU (1) HUE051496T2 (ro)
IL (1) IL257761B2 (ro)
LT (1) LT3350223T (ro)
MA (2) MA52643A (ro)
MD (1) MD3350223T2 (ro)
MX (1) MX2018003185A (ro)
PE (1) PE20181080A1 (ro)
PH (1) PH12018500580A1 (ro)
PL (1) PL3350223T3 (ro)
PT (1) PT3350223T (ro)
RS (1) RS60703B1 (ro)
SI (1) SI3350223T1 (ro)
TW (1) TWI703158B (ro)
UA (1) UA125284C2 (ro)
WO (1) WO2017049024A1 (ro)
ZA (1) ZA201801427B (ro)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP2760889A4 (en) 2011-09-30 2015-04-15 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES AGAINST TL1A AND USES THEREOF
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
IL294038A (en) * 2015-12-04 2022-08-01 Univ Iowa Res Found Device, systems and methods for prediction, screening and monitoring of encephalopathy / delirium
KR102464372B1 (ko) 2016-03-17 2022-11-04 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CN110121509B (zh) 2016-10-26 2024-05-07 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
WO2018199337A1 (ja) * 2017-04-28 2018-11-01 味の素株式会社 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
KR20210005169A (ko) 2018-04-25 2021-01-13 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
MX2022004942A (es) 2019-10-24 2022-07-27 Prometheus Biosciences Inc Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
WO2024026386A1 (en) 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibody formulations
WO2024026395A1 (en) 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1667730B1 (en) 2003-08-20 2013-06-26 University of Miami Compositions and methods for treating inflammatory lung disease
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
WO2006127900A2 (en) 2005-05-25 2006-11-30 Biogen Idec Ma Inc. Tl1a in the treatment of disease
EP1919954B1 (en) 2005-08-30 2016-10-19 University of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
US20090269345A1 (en) 2005-12-23 2009-10-29 Rong Fan CLN248 Antibody Compositions and Methods of Use
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
WO2008106451A2 (en) 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009064854A2 (en) 2007-11-13 2009-05-22 Cogenesys, Inc Humanized antibodies against tl1a
US20120073585A1 (en) 2009-04-08 2012-03-29 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
US20130195884A1 (en) 2009-12-31 2013-08-01 Deutsches Krebsforschungszentrum Novel modulators of trail signalling
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
MX2013013329A (es) 2011-05-20 2014-04-16 Us Government Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos.
EP2760889A4 (en) 2011-09-30 2015-04-15 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES AGAINST TL1A AND USES THEREOF
EA201591153A1 (ru) 2013-01-02 2016-01-29 Гленмарк Фармасьютикалс С.А. Антитела, связывающиеся с tl1a, и их применение
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
MX2015013901A (es) * 2013-04-05 2015-12-11 Genentech Inc Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
US20160096885A1 (en) 2013-05-17 2016-04-07 Cedars-Sinal Medical Center Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
AU2014317991A1 (en) 2013-09-06 2016-03-10 Cedars-Sinai Medical Center Systems, devices and methods for anti-TL1A therapy
IL245001B2 (en) 2013-11-13 2023-05-01 Pfizer Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses
US10519485B2 (en) 2015-04-15 2019-12-31 Biosearch Technologies, Inc. Dual quencher probes
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS

Also Published As

Publication number Publication date
IL257761B2 (en) 2023-03-01
IL257761A (en) 2018-04-30
SI3350223T1 (sl) 2020-10-30
EP3350223B1 (en) 2020-06-17
EP3350223A1 (en) 2018-07-25
DK3350223T3 (da) 2020-08-24
US10138296B2 (en) 2018-11-27
KR20180048712A (ko) 2018-05-10
BR122021002400A8 (pt) 2023-01-24
ZA201801427B (en) 2019-06-26
IL257761B (en) 2022-11-01
HUE051496T2 (hu) 2021-03-01
HRP20201323T1 (hr) 2020-11-27
BR112018005407A2 (pt) 2018-10-09
CO2018003736A2 (es) 2018-07-10
EA201890756A1 (ru) 2018-08-31
CA2997015A1 (en) 2017-03-23
AU2016323460A1 (en) 2018-03-29
CY1123499T1 (el) 2022-03-24
PL3350223T3 (pl) 2021-03-08
US11220549B2 (en) 2022-01-11
PT3350223T (pt) 2020-08-05
MX2018003185A (es) 2018-08-01
AR106055A1 (es) 2017-12-06
JP2022051771A (ja) 2022-04-01
BR112018005407A8 (pt) 2023-01-24
TW201722990A (zh) 2017-07-01
JP7341259B2 (ja) 2023-09-08
US20220185902A1 (en) 2022-06-16
AU2023203440A1 (en) 2023-06-29
MA42825B1 (fr) 2020-09-30
US20170081400A1 (en) 2017-03-23
US20190106486A1 (en) 2019-04-11
RS60703B1 (sr) 2020-09-30
HK1251002A1 (zh) 2019-01-18
LT3350223T (lt) 2020-10-26
JP2018528773A (ja) 2018-10-04
HK1256300A1 (zh) 2019-09-20
JP7013366B2 (ja) 2022-02-15
PE20181080A1 (es) 2018-07-05
EP3693393A1 (en) 2020-08-12
UA125284C2 (uk) 2022-02-16
CN108137693A (zh) 2018-06-08
TWI703158B (zh) 2020-09-01
AU2016323460B2 (en) 2023-06-15
PH12018500580A1 (en) 2018-10-15
WO2017049024A1 (en) 2017-03-23
ES2810751T3 (es) 2021-03-09
CN108137693B (zh) 2021-11-26
BR122021002400A2 (ro) 2018-10-09
MA52643A (fr) 2021-03-24
KR101998535B1 (ko) 2019-07-09
CL2018000711A1 (es) 2018-11-23

Similar Documents

Publication Publication Date Title
MD3350223T2 (ro) Anticorpi care se leagă specific la TL1A
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
MX2018002068A (es) Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes.
MX2017012429A (es) Anticuerpos dirigidos contra la inmunoglobulina de celulas t y la proteina mucina 3 (tim-3).
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201891992A1 (ru) Химерные рецепторы и способы их применения
WO2015106080A3 (en) Antibodies directed against interleukin-33 (il-33)
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
PH12016500943A1 (en) Aplnr modulatros and uses thereof
EA201790441A1 (ru) Антитела к il-25 и их применения
WO2017136562A3 (en) Bispecific binding proteins for pd-l1 and kdr
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
WO2016014434A3 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
EA202091557A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
MX2014007170A (es) Moleculas de anticuerpo de union a trombina y sus usos.
EA202190304A1 (ru) Химерные рецепторы к steap1 и способы их применения
WO2015187521A3 (en) Anti-blys antibodies
MY197821A (en) Anti-il-22r antibodies
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
MX2017013014A (es) Anticuerpo dirigido contra proteinas de union a inmunoglobulinas de s. aureus.
WO2015116569A3 (en) Antibodies directed against discoidin domain receptor family, member 1 (ddr1)